论文部分内容阅读
目的:探讨针对肿瘤化疗患者,选择托烷司琼+胃复安完成治疗后,在缓解恶心以及呕吐症状获得的临床效果。方法:选择我院2011年1月1日-2013年12月31日肿瘤化疗患者100例。通过随机数表法完成所有肿瘤化疗患者的随机分组,设为A1组(治疗组30例)与A2组(对照组70例)。针对A2组肿瘤化疗患者,选择托烷司琼给予临床治疗;针对A1组肿瘤化疗患者,选择托烷司琼+胃复安给予临床治疗。对比A1组与A2组肿瘤化疗患者完成治疗后,在缓解恶心、呕吐症状方面表现的差异性。结果:在治疗总有效率方面,两组肿瘤化疗患者表现出显著差异(P<0.05);针对A1组肿瘤化疗患者,恶心呕吐症状诸多表现为1度以及2度。结论:针对肿瘤化疗患者,选择托烷司琼+胃复安给予临床治疗,在缓解临床恶心呕吐症状两方面,表现了显著意义。
OBJECTIVE: To investigate the clinical effect of naloxone and metoclopramide in the treatment of patients with tumor chemotherapy after the treatment with tropisetron and metoclopramide, and to relieve the symptoms of nausea and vomiting. Methods: One hundred patients with chemotherapy in our hospital from January 1, 2011 to December 31, 2013 were selected. All patients undergoing chemotherapy and chemotherapy were randomized into groups A1 and A2 (control group, 30 cases) and A2 group (randomized control group). For group A2 tumor chemotherapy patients, select tropisetron for clinical treatment; for group A1 tumor chemotherapy patients, select tropisetron qi metoclopramide for clinical treatment. Comparison of A1 and A2 groups after completion of treatment of cancer patients in the treatment of nausea and vomiting symptoms showed differences. Results: There was a significant difference (P <0.05) between the two groups in terms of overall response rate (P <0.05). For patients with A1 tumor, the symptoms of nausea and vomiting were mostly 1 degree and 2 degrees. Conclusion: For patients with tumor chemotherapy, the choice of tropisetron plus metoclopramide given clinical treatment, in relieving clinical symptoms of nausea and vomiting, showed significant.